JP2022524337A5 - - Google Patents
Info
- Publication number
- JP2022524337A5 JP2022524337A5 JP2021552717A JP2021552717A JP2022524337A5 JP 2022524337 A5 JP2022524337 A5 JP 2022524337A5 JP 2021552717 A JP2021552717 A JP 2021552717A JP 2021552717 A JP2021552717 A JP 2021552717A JP 2022524337 A5 JP2022524337 A5 JP 2022524337A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- composition according
- protein composition
- seq
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814159P | 2019-03-05 | 2019-03-05 | |
| US201962814210P | 2019-03-05 | 2019-03-05 | |
| US62/814,210 | 2019-03-05 | ||
| US62/814,159 | 2019-03-05 | ||
| US201962814744P | 2019-03-06 | 2019-03-06 | |
| US62/814,744 | 2019-03-06 | ||
| US201962826523P | 2019-03-29 | 2019-03-29 | |
| US62/826,523 | 2019-03-29 | ||
| PCT/US2020/021276 WO2020181145A1 (en) | 2019-03-05 | 2020-03-05 | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022524337A JP2022524337A (ja) | 2022-05-02 |
| JP2022524337A5 true JP2022524337A5 (enExample) | 2023-03-13 |
Family
ID=70058513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552717A Ceased JP2022524337A (ja) | 2019-03-05 | 2020-03-05 | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220144949A1 (enExample) |
| EP (1) | EP3934761A1 (enExample) |
| JP (1) | JP2022524337A (enExample) |
| CN (1) | CN114173876A (enExample) |
| AU (1) | AU2020231391A1 (enExample) |
| CA (1) | CA3132651A1 (enExample) |
| WO (1) | WO2020181145A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| CN111356700A (zh) | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| EP4416185A4 (en) * | 2021-10-15 | 2025-09-03 | Harpoon Therapeutics Inc | CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE10231109A1 (de) | 2002-07-10 | 2004-01-22 | Daimlerchrysler Ag | Abgasturbine |
| MX2017003847A (es) * | 2014-09-25 | 2017-12-15 | Amgen Inc | Proteinas biespecificas activables por proteasas. |
| FI3377103T4 (fi) * | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
| CN109071667A (zh) | 2016-03-08 | 2018-12-21 | 马弗里克治疗公司 | 可诱导性结合蛋白和使用方法 |
| US11535668B2 (en) * | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CN111315773A (zh) | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | 含有Fc区的条件性活化的结合部分 |
| CN111356700A (zh) * | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| BR112020023330A2 (pt) * | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| US20210309756A1 (en) * | 2018-08-09 | 2021-10-07 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
-
2020
- 2020-03-05 JP JP2021552717A patent/JP2022524337A/ja not_active Ceased
- 2020-03-05 CN CN202080033827.6A patent/CN114173876A/zh active Pending
- 2020-03-05 EP EP20716051.6A patent/EP3934761A1/en not_active Withdrawn
- 2020-03-05 CA CA3132651A patent/CA3132651A1/en active Pending
- 2020-03-05 WO PCT/US2020/021276 patent/WO2020181145A1/en not_active Ceased
- 2020-03-05 AU AU2020231391A patent/AU2020231391A1/en not_active Abandoned
- 2020-03-05 US US17/435,931 patent/US20220144949A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022524337A5 (enExample) | ||
| JP7826370B2 (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| JP2022524338A5 (enExample) | ||
| JP2022524337A (ja) | 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質 | |
| JP2020534811A (ja) | Ｆｃ領域を含有する条件的に活性化された結合部分 | |
| AU2018280683B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| CN114390938B (zh) | 受约束的条件性活化的结合蛋白 | |
| JP2017511130A5 (enExample) | ||
| JP6927618B2 (ja) | 多重特異性タンパク質薬物およびそのライブラリー、ならびに製造方法と使用 | |
| JP2023538366A5 (enExample) | ||
| GB2518221A (en) | Tetravalent antigen-binding protein molecule | |
| US20220218752A1 (en) | Lockr-mediated recruitment of car t cells | |
| CN116745316A (zh) | 具有人血清白蛋白结构域的受限条件激活结合蛋白构建体 | |
| JP2017534296A5 (enExample) | ||
| Kim et al. | Tribody: robust self-assembled trimeric targeting ligands with high stability and significantly improved target-binding strength | |
| US12128102B2 (en) | Constrained conditionally activated binding proteins | |
| WO2023143273A1 (zh) | 新型长效化和高活性且更安全的抗体构建体 | |
| JP2011079758A (ja) | タンパク質と微粒子との複合体及びその製造方法 | |
| RU2024106011A (ru) | Белки, которые разобщают опосредуемую t-клетками противоопухолевую цитотоксичность и высвобождение провоспалительных цитокинов | |
| RU2018134949A (ru) | Индуцибельные связывающие белки и способы использования | |
| CN110540998A (zh) | 一种快速构建多价抗体表达载体的方法和试剂 | |
| EA049569B1 (ru) | Ограниченные условно активируемые связывающие белки |